Acurx Pharmaceuticals, Inc. (ACXP)
ACXP Stock Price Chart
Explore Acurx Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ACXP price movements and trends.
ACXP Company Profile
Discover essential business fundamentals and corporate details for Acurx Pharmaceuticals, Inc. (ACXP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jun 2021
Employees
4.00
Website
https://www.acurxpharma.comCEO
David P. Luci CPA,
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Financial Timeline
Browse a chronological timeline of Acurx Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.61.
Earnings released on 11 Aug 2025
EPS came in at -$1.89 surpassing the estimated -$2.00 by +5.50%.
Stock split effective on 5 Aug 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2025
EPS came in at -$2.20 falling short of the estimated -$0.15 by -1.37K%.
Earnings released on 17 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%.
Earnings released on 12 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.
Earnings released on 9 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%.
Earnings released on 14 May 2024
EPS came in at -$0.28 falling short of the estimated -$0.24 by -16.67%.
Earnings released on 15 Mar 2024
EPS came in at -$0.38 falling short of the estimated -$0.26 by -46.15%.
Earnings released on 13 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%.
Earnings released on 14 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.
Earnings released on 12 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.
Earnings released on 16 Mar 2023
EPS came in at -$0.28 falling short of the estimated -$0.25 by -12.00%.
Earnings released on 14 Nov 2022
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 15 Aug 2022
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%.
Earnings released on 11 May 2022
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%.
Earnings released on 17 Mar 2022
EPS came in at -$0.23 surpassing the estimated -$0.40 by +42.50%.
Earnings released on 12 Nov 2021
EPS came in at -$0.46 .
Earnings released on 16 Aug 2021
EPS came in at -$0.57 .
Earnings released on 28 Jun 2021
EPS came in at -$0.11 .
Earnings released on 31 Mar 2021
EPS came in at -$0.15 .
Earnings released on 30 Sept 2020
EPS came in at -$0.14 .
ACXP Stock Performance
Access detailed ACXP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.